Article

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and <i>in silico</i> trials

2025-12-19

Abstract excerpt

Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [ 177 Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but it...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d6342f84-d45d-58ac-8ed0-d8b67ece0340
DOI: 10.64898/2025.12.17.694859

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and <i>in silico</i> trialsDOI 10.64898/2025.12.17.694859Read

Modular mechanistic mathematical models for improved biomarker identification and treatment scheduling in oncologySemantic proximity Read

Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI- Driven BiomarkersSemantic proximity Read

PSMA-CAR-T Cells for Metastatic Castration-Resistant Prostate Cancer: An Integrated Framework for Translational OptimizationSemantic proximity Read

<p class="MsoNormal" style="margin-bottom: 12.0pt; text-align: left; mso-line-height-alt: 14.0pt; layout-grid-mode: char; mso-layout-grid-align: none;" align="left">Evaluation of <sup>177</sup>Lu-PSMA-617 Based Targeted Radioligand Therapy with X-Ray Stimulated PSMA Relocation in the <em>PiggyBac</em> Reporter Gene Engineered Orthotopic Prostate Tumor ModelSemantic proximity Read

Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination TherapySemantic proximity Read

Dosimetry-Driven Alpha Emitter Selection for Radioligand Therapy: Is daughter translocation a significant safety concern?Semantic proximity Read

Creation of MLPA: A Multi-level Digital Twin Framework for Personalized Cancer Simulation and Treatment OptimizationSemantic proximity Read

Predicting Treatment Outcomes from Adaptive Therapy — A New Mathematical BiomarkerSemantic proximity Read

Dynamic optimization of chemo–immunotherapy sequencing reveals phenotype-dependent regimens across tumor immune microenvironmentsSemantic proximity Read

A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the ‘Seed and Soil’ ParadigmSemantic proximity Read

Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy. Implications for Radiopharmaceutical Repurposing (Beyond Oncology)Semantic proximity Read

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read